Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder
NCT06934915
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn how prednisone affects adults with autism spectrum disorder (ASD). It will also learn about the safety of prednisone. The main questions it aims to answer are: How does prednisone affect the core features and associated target symptoms of ASD in adults with an immune-mediated subtype of ASD? Is prednisone safe for autistic adults without causing too many side effects? Does this study warrant larger trials studying anti-inflammatory drugs in this subject population?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder
- Autism Spectrum Disorders
- Autistic Disorder
- Autism
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 50 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Christopher John McDougle, M.D.
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- MGH Lurie Center for Autism · Lexington, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.